Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL -4.02%32 3-Year EBITDA Growth Rate is 14.20% as of Jun. 2026, which is 13% below its 10-year median of 16.40. GuruFocus rates HOWL with a GF Score™ of 32/100 and a GF Value™ of $3.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Werewolf Therapeutics ranks worse than 51.02% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Werewolf Therapeutics was 28.40% per year. The lowest was -18.20% per year. And the median was 16.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Werewolf Therapeutics 3-Year EBITDA Growth Rate Related Terms
HOWL vs CVM, MRKR, ZIVO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Werewolf Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.20% mean?
Werewolf Therapeutics (HOWL) has a 3-Year EBITDA Growth Rate of 14.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Werewolf Therapeutics and its competitors. This is 13% below median its historical median of 16.40. According to the industry distribution chart, Werewolf Therapeutics ranks #577 out of 1131 companies in the Biotechnology industry, placing it in the top 51%.
Is Werewolf Therapeutics' 3-Year EBITDA Growth Rate too high?
Werewolf Therapeutics' current 3-Year EBITDA Growth Rate of 14.20% is 13% below median its 10-year median of 16.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Werewolf Therapeutics' value of 14.20% is 4.7% below this industry median. Based on the distribution chart, Werewolf Therapeutics ranks #577 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Werewolf Therapeutics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' 3-Year EBITDA Growth Rate compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #577 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Werewolf Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Werewolf Therapeutics' value of 14.20% is 4.7% below this benchmark. While the company's 10-year median is 16.40 vs. the industry median of 14.90, Werewolf Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Werewolf Therapeutics's current 3-Year EBITDA Growth Rate of 14.20% is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Werewolf Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current 3-Year EBITDA Growth Rate is 14.20%, which is 13% below median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Werewolf Therapeutics (HOWL) is currently considered Possible Value Trap. The stock's GF Value™ is $3.78, compared to a current price of $0.38 — trading 89.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 14.20%, which is 13% below median its 10-year median of 16.40 and 4.7% below the Biotechnology industry median of 14.90. Werewolf Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current 3-Year EBITDA Growth Rate is 14.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Werewolf Therapeutics (HOWL) Overvalued in 2026?
Based on GuruFocus' analysis, Werewolf Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 89.9% below its estimated GF Value™ of $3.78.
GuruFocus considers Werewolf Therapeutics to be Possible Value Trap.
Key valuation signals for HOWL:
3-Year EBITDA Growth Rate: 14.20% (13% below median its 10-year median of 16.40)
GF Value™: $3.78 vs. price of $0.38 (89.9% below fair value)
Industry Position: 4.7% below the Biotechnology median (#577 of 1131)
No single metric tells the full story. See the HOWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
32GF Score
Get the complete analysis for HOWL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
